top of page

NeuroDerm starts phase III trial of NDO612L in Parkinson's disease

Clinical stage pharmaceutical firm NeuroDerm has started a phase III clinical trial, evaluating NDO612L for the treatment of Parkinson's disease (PD).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page